Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).
Newcastle Disease Virus Vaccine (MTH-68/H) was administered to patients suffering from advanced neoplastic diseases after non-efficient tumor-destructive treatment. Case reports of selected patients suggest promising effects of this treatment. A prospectively-randomized clinical study (phase III; in accordance with Good Clinical Practice, GCP) was proposed to confirm these results and is currently under consideration.
Csatary
L K
LK
United Cancer Research Institute, Alexandria, VA, USA.
Moss
R W
RW
Beuth
J
J
Töröcsik
B
B
Szeberenyi
J
J
Bakacs
T
T
D000328:Adult; D000368:Aged; D019496:Cancer Vaccines / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008207:Lymphatic Metastasis; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D009522:Newcastle disease virus / Q000276:immunology*; D016066:Pleural Effusion, Malignant / Q000628:therapy; D012074:Remission Induction; D012878:Skin Neoplasms / Q000556:secondary / Q000628:therapy; D016896:Treatment Outcome
D019496:Cancer Vaccines